<SEC-DOCUMENT>0001193125-14-048442.txt : 20140212
<SEC-HEADER>0001193125-14-048442.hdr.sgml : 20140212
<ACCEPTANCE-DATETIME>20140212172909
ACCESSION NUMBER:		0001193125-14-048442
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140211
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140212
DATE AS OF CHANGE:		20140212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		14601600

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d676869d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;12, 2014 (February 11, 2014) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2014, the Board of Directors (the &#147;Board&#148;) of
ARCA biopharma, Inc. (the &#147;Company&#148;) elected Daniel J. Mitchell as a director of the Company to fill a vacancy on the Board. Mr.&nbsp;Mitchell was elected for a term expiring at the Company&#146;s 2015 annual stockholders&#146; meeting.
Mr.&nbsp;Mitchell was also appointed to serve on the Board&#146;s Audit Committee and Nominating and Corporate Governance Committee. A copy of the press release announcing Mr.&nbsp;Mitchell&#146;s appointment is attached hereto as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mitchell founded and is a Manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to
founding Sequel Venture Partners, Mr.&nbsp;Mitchell was a founder in 1986 of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner until 2006. On behalf of Sequel Ventures, Mr.&nbsp;Mitchell led
the 1998 Series A financing that initially funded Myogen, Inc., a biopharmaceutical company focused on cardiovascular diseases, participated in subsequent financing rounds and served on the board of directors until Myogen was acquired in 2006. He
served on the board of directors of Replidyne, Inc., a publicly-traded pharmaceutical company, from 2002 until the company was acquired in 2009. Mr.&nbsp;Mitchell currently serves on the board of directors of several private companies.
Mr.&nbsp;Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with Mr.&nbsp;Mitchell&#146;s election, Mr.&nbsp;Mitchell and the Company entered into an Indemnity Agreement, in the same form used with the Company&#146;s other directors.&nbsp;The Indemnity Agreement generally requires the Company to indemnify
Mr.&nbsp;Mitchell against liabilities incurred in the performance of his duties to the Company to the maximum extent permitted by Delaware corporate law and the Company&#146;s certificate of incorporation and bylaws.&nbsp;The Company&#146;s standard
form of Indemnity Agreement is filed as Exhibit&nbsp;10.52 to its Annual Report on Form 10-K filed on March&nbsp;27, 2009. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151;
Financial Statements and Exhibits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;Dan Mitchell Joins ARCA biopharma Board of Directors&#148; dated February 12, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February&nbsp;12, 2014 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">SVP and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;Dan Mitchell Joins ARCA biopharma Board of Directors&#148; dated February 12, 2014.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d676869dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g676869g91g31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DAN MITCHELL JOINS ARCA BIOPHARMA BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, February&nbsp;12 2014</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced that Dan Mitchell has been appointed to the Company&#146;s Board of Directors. He will serve on the Audit and Nominating and Corporate Governance Committees of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mitchell founded and is a Manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture
Partners, Mr.&nbsp;Mitchell was a founder in 1986 of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner until 2006. On behalf of Sequel Ventures, Mr.&nbsp;Mitchell led the 1998 Series A
financing that initially funded Myogen, Inc., a biopharmaceutical company focused on cardiovascular diseases, participated in subsequent financing rounds and served on the board of directors until Myogen was acquired in 2006. He served on the board
of directors of Replidyne, Inc., a publicly-traded pharmaceutical company, from 2002 until the company was acquired in 2009. Mr.&nbsp;Mitchell currently serves on the board of directors of several private companies. Mr.&nbsp;Mitchell holds a B.S.
from the University of Illinois and an M.B.A. from the University of California at Berkeley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are honored to have Dan join the ARCA Board of
Directors,&#148; said Dr.&nbsp;Michael&nbsp;R. Bristow, President and Chief Executive Officer of ARCA. &#147;With his significant expertise and experience in identifying investment worthy companies and helping to advise those companies in managing
their growth, Dan will be a valuable addition to the ARCA Board as we continue the development of Gencaro and look to deliver value to our stockholders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am delighted to join the Board of ARCA at this important point in its development,&#148; said Mr.&nbsp;Mitchell. &#147;The imminent initiation of the
GENETIC-AF trial evaluating ARCA&#146;s Gencaro as potentially the first genetically-targeted atrial fibrillation prevention treatment is a tremendous step in hopefully addressing what we believe is an unmet medical need for new atrial fibrillation
treatments. ARCA&#146;s personalized medicine approach to drug development has identified both the compound and the regulatory pathway to potentially achieve that goal.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to
developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic
variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial
fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether
they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s
intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g676869g91g31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g676869g91g31.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%(`V`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`9+*D,3RR':B`L3Z"IG)0BY2V0TFW9'%ZEXEN[F9DM'
M,$`.`5^\WOGM7S&)S.K4E:F[+\3TJ>'C%>]JRE'=ZE)G%]<\#/\`K6_QKC6(
MQ#VF_O9HX4UT1,)]1,;-]MN>"/\`EJW^-6JV(M?G?WL7+3[(C>ZU)%W?;KGV
M_>M_C4/$8A*[F_O8U"GV0^S\0:C9R`O,TT?=9#G/X]:VHYA7I/5W7F3.A"2V
ML=Q9W<=[:1W$1^1QGZ>U?54:L:T%..S/,G%PERLGK4D*`,7Q/XDMO"^DB^N(
MS+EPBQJ<%B>OY#)I-V&E<UH9H[B".:)@T<BAE([@C(IB)*`,S6-6ETI(WCTN
M\OE;.[[,H8ICU!(_2D,Y5OBSH4;F-[/4$D4[2AA`(/I]ZE<?*:7_``FDOE^=
M_P`(OK7DXSN\@=/7&[-.XK%K0_&NB:_-]GM+EH[K_GA,NQ_P'?\`"BX6L=#3
M$-=TC1G=@B*,EF.`!0!R<_Q!TU[TV6CVMUJ]R.HM4^4?5CQ2N.Q,^O\`B1(O
M-/A"0KUVK>QEORHU"R,VV^)UD^JQ:;>Z3?65T\BQ[9`ORDG`SSTI7'8[JJ)"
M@#%\3^([?POI/VZXC,N75$C4X+$_X#)I-V&E<UH)H[FWCGB;='(H=3Z@C(IB
M)*`"@#+\1DKH%U@XX4?^/"N#,7;"R^7YHWP_\1'$6T+,0P'%?)1BV[GIMV-Z
MQL0^V:%=Q4_/'W_#U%>I0H7M.'3='-.=M&7S80*D\*2IEF&WGH/>NQX>"4H*
M2W5C+VDM&T5[W3E!+'Y((P%4]V^E8U\,D[O2*T]2H5.G4YZY@))*KA1^0KQY
MQ=[I'7%G4>$2?[*D4G@2G'Y"OH\H=Z#]3@Q7QF_7KG*%`'DOQ#6Z\176HM:M
MFST)%W@?QR,?F_(5+*6ATGPOUG^TO"JVDC9FL6\H_P"[U7_#\*$)G;50@H`\
M)\0JH^+3#`P;V+(_[YJ.I:V/=JL@\,^)D*Z9XX%S9GR97C2?*<8?)Y_05#W+
M6Q[5IT[W.F6EQ(-LDL2NP]"0":H@\D\:>(;WQ5XE3PUI4A6U$HA.#Q*^>2?]
MD<_E4O4M*QZ?X?T"Q\.:9'9648&!^\D(^:1O4U6Q+9JTQ',>,_#"Z[81W%K$
MO]J6KK)`^=I.#DJ3Z?UI-#3L=,I)4%A@XY'I3$+0!Y-\0UNO$5UJ)M6S9Z%&
MID`_CD8_-^2U+*6AT7PNUG^TO"PM)&S-8MY9_P!P\K_4?A0A,[>J$%`&7XC_
M`.0#<_\``?\`T(5Y^9?[K+Y?FC?#_P`1'*Z>A#`K,B'U+8KYO#QUNG8]";\C
M;OIVM]-WJT1D=@A>/@@'KG\J]6O-TZ',FKO2Z.6$>:=A^FO"J#=BEA907Q!4
M3Z%OS(Y!(H\O"<J9.@S74I1DFM--KF=FK'/:DC,Q+SQO]#T_"O'Q*;>LDSKI
MNVR-?PF,:;-_UU/\A7K91_`?J<V*^-&_7L'(9NOZM'H6A7FHR8Q!&2H_O-T4
M?GBEL-&#X1LK.V\(B"_N86N-0#376Z09)?J#^%)`]S@?`EXWAGQ_+I<L@,,S
MM;%@<@D'Y#_GUI+1E/8]NJR`H`\&\42B#XJ32E'<)=Q-M098X"\`=S4=2UL>
MAZC\3M'TW*366HI/C(BDMS&3^=.Y-C(TSPG<^,M:3Q/KCQ+9R[6@M8GW94?=
M#'T]1]>E%KCO;0]#U&9K72KN:,8:*%V7'LI(IDGBWPJA6X\:"63EHX'<$^IP
M,_J:E%O8]SJR`H`*`"@#.U[5H]#T.[U&7I!&2H_O-T`_$XI;#1@>$+.TMO"7
ME:A<P-<:B&FNMT@R2_8_A20/<X'P-=GPQ\0)=+ED!AF=K8L#D$Y^0_Y]:2T9
M3V/;JL@*`,KQ)QH%S_P'_P!"%>?F7^ZR^7YHWP_\1'(64L:$%@6]@<5\O2E&
M+U/1DGT.B1XKJP:*X58X7X1$'S$^M>S&4*E)QJ*R>R6_J<C3C*\=RL-(NX'9
M5NX3&A`+'((_"L?J52#:4U9%^VB^A>`%G!)#&PDG!S('7[X]JZM*,7"+O+K?
MKZ&7QM-['/7T\<A)5-A]`<BO&K3C+96.R":-[PB<Z9+_`-=3_(5[F4?P'ZG'
MBOC1T%>P<AP?BYO^$@\6:3X73YK=&^U7@_V1T4_Y[BI?8I:*YO?\(5X9_P"@
M'9_]^Q3LA79YG\2_#T/A_5+'4-+@6V@D&`L8P%D4Y!_+^52U8I,]8T#54UK0
M;+44_P"6T8+#T;H1^>:I$O0TJ8CPKQ#_`,E;/_7[%_[+4=2^AZGXR\,Q>)M#
MDMP%%W%\]O(>S>GT/2J:)3L>??#;Q1)HVIOX>U,F.&60K'O_`.64O=3['^?U
MJ4RFCV":)9H9(G&4=2I'L:L@\'\-RMX-^(B6][\B1R-;R,>!M;HWTZ&H6C+W
M1[W5D!0`V1TBC:1V"H@+,3T`%`%;3-1M]6TZ&^M2Q@F!*%EP2,XSBD&QQWB]
M_P"W_%6D>%D^:`-]JO`/[@Z`_P">XI/L4M-3>_X0KPS_`-`.S_[]BG9"NSS/
MXE^'8-`U*QU#2X%MH)!C$8P%D4Y!_+^52U8I,]8\/ZJFMZ#9:BF,S1@L!V;H
MP_/-42]#2IB*>JVAO=+N+=?O.OR_4<C^5<V*I.M1E!=32E+DFF>>%9+6=HY4
M*NAPRGL:^,E&4)6DM4>NFI*Z+]K?%)1(QR5Y&?7M6].LXRYGT,Y0NK%I=1/V
M>52V2S`G]:V6(?))/K8CV>J(+F_,BHV?G4;2?IT-95*[E9]2HPMH9LTQE;/<
M_K7,VY.[-4K'=>'K)['2D648D<ER/3-?6Y?1=&@E+=ZGEUYJ<]!FMZY)I("0
M:3?7\[+N5;>+*_0MVKOV,4C@O"UWK>F>(]3U?6_#VHO)>@8DAAW>6`?NX].G
MY4D-GJ43^;$D@5EW*#M88(SZCUJB3S_X@W%QKFE2:39:#J4\\<P(F\C$8QU(
M/?(J64M#*\$7_B/PO`]C?^'=0FL6;>IBBRT9/7CN*%H#U._O/$(M+&VN5TK4
MIS<*2L45N2Z8[,/X:8K'D>I:;XFO_%KZZGAR\0&=95B*=EQ@'\JDH]<T;7GU
M5S%+I&H6$JIN/VF':OT#=ZHFUCA?B5X+N;F\CUG2+5Y99"%GBB7+9[.!^A_"
MDT-,V/#WBG7;;3XK;7?#FIM)&H7[1%#OWCU8=<T)A8N^,?!%KXKMTN(F%MJ"
M+A)"O##^ZP_SBFU<2=C(T77O$7A:%=.\1Z1=7-M$-L=Y;+YN%[`XZ_SI;#LF
M;W_"?:%LRCW;O_SS6TD+?EMIW%8Y7Q1J_BGQ3:-8:-H-[;6,G#RS+L>0>G/0
M4G=C5D=;+J#^&-&L;"WTF]OIH[=55;:+*Y`QRW0<T]A;G&^%[O6]-\2ZEK&M
M^'M1=[U<!X8=WE@'[N/3&/RI(;/4XI/-A20*RAU#;6&",]B.QIDG`?$&XN-;
MTJ72++0=2GG28$3>1B,8ZD'OD4F4M#)\#WWB+PO"]CJ'A[4);!VWJT<66C/?
MCN#0M`>IZI;S">WBF".@D4,%==K+D9P1V-4224`4;[2++4,&XA!<='4X/YUR
MU\)1KZS6IK"K.&S*'_"):<.C3_\`??\`]:N/^R</Y_>:_6IB_P#"*:?C&^?_
M`+['^%']DX?N_O#ZU,3_`(1/3O[\_P#WW_\`6H_LG#^?WA]:F6K/0-/L9!)'
M"6D'1G.<5T4<!0HOFBM?,SG7G-6;-.NXQ$)"@DG`'4F@"&WO;>[:06\JR>6<
M,5Y`/UI#M8GIB(XIHITWPR+(N<94Y%("2F`4`%`",P12S$!1R2>U`$-M>6]W
MO^SRB0(<,5Z9^M(=K$],04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M%74KM;'3I[AOX%X'J>PI;#1CZ)>6]C#:V120RW!+&4+\A?J1GOZ4D-HV+Z^@
ML+=I)LD`$[5&213V$E<33DMH["-[6$00R#S-N,8SZT(&0#6K8X=5<VYD\L38
M^4M[=\>]%PL7;BYBM(&FF<*B]Z-A&-IVN2,D)OXG07,A$+A1MQV'K23*:[&I
MJ-RMGIT]PW\"$@>I[4]A(Q=+U"WTK3;:.2.1O-?YY57Y0[=LTD[#:N=&2`,D
MX`JB3.GUF"%X42.64S/L0JO#'V)I7'8LWM]%80&67<<`D*HR3BC8$KE6#6X+
MB6W2*&8B8??V?*IQG!-%PM8EU'5;?34!E#L<CA!G&?6B]@2N0MKUHMVD#+*`
MZED<KPWT[FBX6)[#4H]0,ZI')&T+;6#C!S1<&K%B>XCMPN\G<W"JHR6^@H$5
M['4DOY)UCBD586VEG&,GN/PHN-JQ=IB"@`H`*`"@`H`*`"@`H`P/$#QRWMA9
MW#^7:LQDD8]#CH*EE(M06YO;^*Z,9CM;=2($(P23U;'8>E,6Q5UR47%];:=M
M8JW[R0*.6`Z*/J:3&BYK8F&A7`@4A]@&%[#O^E-["6Y0EA6]^P:99\VUOM>:
M1?NC'09]32\A[:ECQ+<>7IZVRMA[EPF?1>YH81(Y;=+^^L;>VYM++YG<="1T
M4>M`;$FO*;R2TTY<A97WR$=D6A@M-1C+;ZN;*&S'^AV[[W.T@<=%YHW#8DUF
M[5+RSLY=P@E):3:"=P'1>/4T,$BI8SO?^(9))(6"VW[N*/'W/5C1U#9%OQ!Y
MD\4&GP@^9<OM+8^ZHY-#!&I;V\=K;QP1+M1!@"F28M[$NJZT('&+.S&^4X^^
MW8?E2W92T14\PK%=:_+&=W^KM4(^Z.@-'F/R-?0X!;Z:HVMN8[F<]7)ZFFB6
M8_\`;#"RO+]$9KLL4!*G$*YP!_6E<JW0VM#A$&F1H%;U+-U<GJ::)9HTQ!0`
M4`%`!0`4`%`!0`4`(5!QD`XH`6@!,#.<<T`+0`@`484`#T%`&-Y%W<>(([F>
MS=;>)"L>74X)ZDC-3U*Z&R`%&``!Z"J)%H`0``8`P*`#`R#CD4```'08H`6@
M`H`*`$(!&",B@!:`$VKC&!CTQ0`M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
>4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
